Organic Active Ingredients TRIZ Cases

Selective norepinephrine inhibitors reduce cataplexy attacks while improving tolerability and access versus scheduled narcolepsy treatments.

Chiral tartaric acid esters resolve this racemate into a >97% ee enantiomer using standard pilot plant equipment and efficient solvent recovery.

Cereblon-binding analogs enable degradation of undruggable oncoproteins, addressing the need for potent and selective cancer modulators.

A controlled oral minoxidil formulation sustains serum levels over time, reducing fluctuation-driven adverse effects in hair loss treatment.

Rapamycin-based mTOR inhibition with enteric coating helps prevent intestinal polyps and cancer risk while improving bioavailability and tolerability.

Combining elacestrant with abemaciclib targets endocrine resistance in ER+ breast cancer and prolongs progression-free survival.

Functional group-guided reselection and analog targets help isolate high-affinity aptamers for sterically hindered small molecules.

Patient-derived liver organoid panels link genetic variants to metabolic phenotypes, improving NAFLD risk prediction and treatment selection.

Oral fasudil at 180-240 mg/day slows functional decline in ALS patients starting treatment 24 months after disease onset.

Long-acting injectable abiraterone prodrugs improve bioavailability, avoid food-driven variability, and reduce daily pill burden.

Formula-based SARS-CoV-2 3CL protease inhibitors curb viral replication while improving efficacy and safety for COVID-19 treatment.

Rotor-stator emulsification forms hormone-loaded liposomes that maintain steadier serum levels for 8 to 32 hours with fewer applications.

Acylsulfonamide KAT6A inhibitors address the lack of approved targeted therapies for KAT6A-driven cancer and autoimmune disorders.

Transient microchannels formed by hydrostatic pressure replace fixed orifices, enabling controlled drug release with lower clogging risk and complexity.

Selected L. fermentum strains, alone or with S. cerevisiae, inhibit Candida hyphal formation while avoiding azole resistance and irritation.

Salt and crystal forms of an allopregnanolone derivative improve solubility, stability, and oral bioavailability for CNS drug formulations.

Peptide-linked self-assembled glucosamine nanoparticles cross the stratum corneum, boost cellular uptake, and reduce cytotoxicity.

5-HT1A/1B receptor agonists address BIND and jaundice-linked psychiatric symptoms while avoiding the side effects seen with existing drugs.

Ribose with glycine, alanine, and glutamine helps resensitize resistant bacteria to antibiotics and reduce UTI recurrence risk.

Natural FOS diluents and fatty acid glyceride lubricants improve powder flow, compressibility, and tablet stability while avoiding synthetic excipients.

PLA-based lumateperone microspheres use release regulators and particle-size control to avoid burst release, shorten lag time, and sustain dosing.

Dual-site Fc glycosylation and K246/K248 lysine conjugation avoids complex branched ADC structures, improving stability and industrialization.

A double-stranded DNA linker lets a bivalent aptamer bind thrombin exosites I and II while enabling complementary-strand reversal.

New rivoceranib and mesylate polymorphs improve handling, stability, and dissolution through controlled slurry mixing and drying.

Small-molecule Formula I inhibitors broaden plasma kallikrein treatment beyond HAE to retinal and inflammatory disorders.

Targeting TGF-β1 signaling with a flavone derivative suppresses EMT and fibrosis-related factors while avoiding lung cell toxicity.

Novel Form CSV and Form CSVI improve nirogacestat dihydrobromide solubility, compressibility, and storage stability for consistent drug quality.

C21-substituted neuroactive steroids improve GABA modulation consistency to treat PMS, postnatal depression, epilepsy, and related CNS disorders.

A hydrochloride salt form of tegoprazan raises aqueous solubility, improves stability, and maintains immediate release across gastrointestinal pH changes.

NTD-targeting androgen receptor modulators inhibit transcriptional activation and address prostate cancer resistance from LBD mutations and AR-Vs.

By inhibiting arginase and restoring L-arginine in the tumor microenvironment, these compounds help recover T-cell activation and anti-tumor response.

Bivalent compounds recruit E3 ubiquitin ligases to degrade TRK proteins, addressing off-target effects and resistance in TRK-mediated disease treatment.

5'-phosphonate nucleoside analogs strengthen oligonucleotide nuclease resistance while preserving RNA targeting and gene silencing activity.

Combining APOC3- and PCSK9-targeting siRNAs overcomes the LDL-c reduction plateau of single-agent therapy in hyperlipidemia.

A flocculated sorbitan ester suspension improves antipsychotic resuspension and extended release while reducing injection site irritation.

A dual-release scaffold delivers factor Xa and IIa inhibitors at injury sites to suppress clotting and inflammation while supporting healing.

ASOs mask UNC13A cryptic exons to restore correct splicing and protein function in TDP-43-linked neurodegenerative disorders.

Selective AHR-inhibiting pyridazine carboxamides help curb tumour growth while modulating dysregulated immune responses in cancer.

Animal tissue-derived plasmalogen activates natural killer cells to strengthen innate immune function where its immune role was previously unclear.

Cyclodextrin-enabled ursodeoxycholic acid injection improves solubility, controls pH, and avoids high-base, large-volume IV formulations.

A novel GWT1-targeting antifungal regimen sustains exposure over 4 weeks to treat resistant invasive fungal infections and improve outcomes.

Heterobifunctional CCR2 CyTaCs recruit exogenous antibodies to boost ADCC and selectively deplete pathogenic cells with better stability.

Copper complexes with tailored ligands target copper metabolism imbalance in ALS, improving motor neuron function and survival.

Controlled aqueous hydroxypropylation and solvent-free purification produce HPβCD with low residual β-CD for safer pharmaceutical excipient use.

Nanoparticles deliver CRISPR/Cas13 with peptides, aptamers, and SORT targeting to knock down disease RNA while avoiding unwanted DNA changes.

Monothioglycerol and controlled aqueous excipients stabilize hydrocortisone sodium phosphate while improving exposure and peak serum concentration.

Small molecules that restore p63 activity improve keratinocyte differentiation and heal severe skin erosions in ectodermal dysplasia.

Pan-selective pyridinone KDM inhibitors tune HP1-mediated gene repression to improve tumor-selective cytotoxicity in cancer cells.

High-throughput kinase screening identifies resistance targets such as COT and CRAF to guide RAF inhibitor combination therapy in cancer.

Five new elafibranor crystalline forms improve shelf life, solubility, purity, and flowability for pharmaceutical formulation.